Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Epizyme would command a market value of $375 million.
Epizyme, which was founded in 2007 and booked $48 million in sales for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on March 22, 2013. Citi, Cowen & Company, and Leerink Swann are the joint bookrunners on the deal.
